The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.

Authors
Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Register
Year 2008
This article has no abstract
Epistemonikos ID: e76241b35feb17b75c237803705b1a227fbf2df1
First added on: Feb 22, 2025